[{"data":1,"prerenderedAt":174},["ShallowReactive",2],{"drug-naloxegol":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":43,"contraindications":70,"warnings":80,"renal":88,"monitoring":98,"interactions":99,"review":100,"examples":103,"atc":109,"iran":111,"usApproval":118,"links":124,"populations":138},"naloxegol",1,{"fa":7,"en":8},"نالوکسگول","Naloxegol","alimentary-metabolism",{"fa":11,"en":12},"آنتاگونیست محیطی گیرنده اپیوئید (PAMORA)","Peripherally acting opioid antagonist (PAMORA)",[14],{"name":15,"market":16},"Movantik","US",[18,19,7],"movantik","موونتیک",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-25","tablet","oral","25 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},25,"mg",false,[16],[32],{"source":33,"section":34},"fda-movantik","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-12-5","12.5 mg tablet",{"amount":39,"unit":28,"perUnit":23,"scored":29},12.5,[16],[42],{"source":33,"section":34},[44],{"id":45,"disease":46,"label":47,"population":50,"type":54,"unit":28,"dose":55,"refs":56,"notes":59},"oic","opioid-induced-constipation",{"fa":48,"en":49},"یبوست ناشی از اپیوئید در درد مزمن غیرسرطانی — ۲۵ mg صبح ناشتا","OIC in chronic non-cancer pain — 25 mg each morning on an empty stomach",{"minAge":51},{"value":52,"unit":53},18,"year","fixed",{"perDose":27,"dosesPerDay":5},[57],{"source":33,"section":58},"2.2",[60],{"text":61,"refs":64},{"fa":62,"en":63},"عدم تحمل: ۱۲٫۵ mg. مهارکننده متوسط CYP3A4: پرهیز یا ۱۲٫۵ mg. ملین نگهدارنده قطع شود.","If not tolerated: 12.5 mg. Moderate CYP3A4 inhibitors: avoid or 12.5 mg. Stop maintenance laxatives.",[65,66,68],{"source":33,"section":58},{"source":33,"section":67},"2.4",{"source":33,"section":69},"2",[71],{"id":72,"severity":73,"text":74,"refs":77},"ci","block",{"fa":75,"en":76},"انسداد گوارشی شناخته یا مشکوک؛ مهارکننده‌های قوی CYP3A4 (کلاریترومایسین، کتوکونازول)؛ حساسیت.","Known or suspected GI obstruction; strong CYP3A4 inhibitors (clarithromycin, ketoconazole); hypersensitivity.",[78],{"source":33,"section":79},"4",[81],{"text":82,"refs":85},{"fa":83,"en":84},"سوراخ‌شدگی گوارش؛ اسهال یا درد شکمی شدید؛ علائم ترک اپیوئید.","GI perforation; severe diarrhoea or abdominal pain; opioid withdrawal.",[86],{"source":33,"section":87},"5",[89],{"egfrBelow":90,"severity":91,"text":92,"refs":95},60,"warn",{"fa":93,"en":94},"ClCr زیر ۶۰: شروع ۱۲٫۵ mg.","CrCl \u003C60: start 12.5 mg.",[96],{"source":33,"section":97},"2.3",[],[],{"status":101,"reviewer":102,"date":102},"unverified",null,[104],{"regimen":45,"formulation":22,"input":105,"expect":108},{"ageYears":106,"weightKg":107},50,75,{"perDose":27,"tabletsPerDoseRounded":5},[110],"A06AH03",{"status":112,"refs":113},"not-found",[114],{"source":115,"section":116,"url":117},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Naloxegol",{"kind":119,"refs":120,"id":123},"NDA",[121],{"source":33,"section":122},"SPL approval \u002F marketing category","NDA204760",[125,128,132,135],{"kind":126,"url":127,"label":123},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=204760",{"kind":129,"url":130,"label":131},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=28596788-b73f-4247-85fc-3105f51fff5a","FDA Movantik",{"kind":133,"url":134,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa615016.html",{"kind":136,"url":137,"label":110},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=A06AH03",{"pregnancy":139,"lactation":148,"pediatric":157,"geriatric":165},{"level":140,"text":141,"quote":144,"refs":145},"caution",{"fa":142,"en":143},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Limited available data with MOVANTIK use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes.",[146],{"source":33,"section":147},"8.1",{"level":149,"text":150,"quote":153,"refs":154},"avoid",{"fa":151,"en":152},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for adverse reactions, including opioid withdrawal in breastfed infants, advise women that breastfeeding is not recommended during treatment with MOVANTIK.",[155],{"source":33,"section":156},"8.2",{"level":140,"text":158,"quote":161,"refs":162},{"fa":159,"en":160},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of MOVANTIK have not been established in pediatric patients.",[163],{"source":33,"section":164},"8.4",{"level":166,"text":167,"quote":170,"refs":171},"ok",{"fa":168,"en":169},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No dosage adjustment is needed in elderly patients.",[172],{"source":33,"section":173},"8.5",1792444412657]